The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial
Open accessAbstract
Importance: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine. Objective: To assess the efficacy of fremanezumab compared with placebo for prevention of episodic migraine with a monthly dosing regimen or a single higher dose. Design and Setting: Randomized, double-blind, placebo-controlled, parallel-group trial conducted at 123 sites in 9 countries from March 23, 2016 (first patient randomized), to April 10, 2017, consisting of a screening visit, 28-day pretreatment period, 12-week treatment period, and final evaluation at week 12. Participants: Study participants were aged 18 to 70 years with episodic migraine (6-14 headache days, with at least 4 migraine days, during 28-day pretreatment period). Patients who had previous treatment failure with 2 classes of migraine-preventive medication were excluded. Interventions: Patients were randomized 1:1:1 to receive subcutaneous monthly dosing of fremanezumab (n = 290; 225 mg at baseline, week 4, and week 8); a single higher dose of fremanezumab, as intended to support a quarterly dose regimen (n = 291; 675 mg of fremanezumab at baseline; placebo at weeks 4 and 8); or placebo (n = 294; at baseline, week 4, and week 8). Main Outcomes and Measures: The primary end point was mean change in mean number of monthly migraine days during the 12-week period after the first dose. Results: Among 875 patients who were randomized (mean age, 41.8 [SD, 12.1] years; 742 women [85%]), 791 (90.4%) completed the trial. From baseline to 12 weeks, mean migraine days per month decreased from 8.9 days to 4.9 days in the fremanezumab monthly dosing group, from 9.2 days to 5.3 days in the fremanezumab single-higher-dose group, and from 9.1 days to 6.5 days in the placebo group. This resulted in a difference with monthly dosing vs placebo of -1.5 days (95% CI, -2.01 to -0.93 days; P < .001) and with single higher dosing vs placebo of -1.3 days (95% CI, -1.79 to -0.72 days; P < .001). The most common adverse events that led to discontinuation were injection site erythema (n = 3), injection site induration (n = 2), diarrhea (n = 2), anxiety (n = 2), and depression (n = 2). Conclusions and Relevance: Among patients with episodic migraine in whom multiple medication classes had not previously failed, subcutaneous fremanezumab, compared with placebo, resulted in a statistically significant 1.3- to 1.5-day reduction in the mean number of monthly migraine days over a 12-week period. Further research is needed to assess effectiveness against other preventive medications and in patients in whom multiple preventive drug classes have failed and to determine long-term safety and efficacy. Trial Registration: clinicaltrials.gov Identifier: NCT02629861.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Self-citationPrevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
Pathophysiology of migraine: a disorder of sensory processing
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00034.2015 · Cited by 1,998
Self-citationVasoactive peptide release in the extracerebral circulation of humans during migraine headache
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990) · Annals of Neurology · doi:10.1002/ana.410280213 · Cited by 1,597
Self-citationA Controlled Trial of Erenumab for Episodic Migraine
Goadsby, P. J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J. H., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1705848 · Cited by 928
Self-citationMigraine: Multiple Processes, Complex Pathophysiology
Burstein, R., Noseda, R., & Borsook, D. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0373-15.2015 · Cited by 838
Fremanezumab for the Preventive Treatment of Chronic Migraine
Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709038 · Cited by 792
Self-citationCGRP and its receptors provide new insights into migraine pathophysiology
Ho, T. W., Edvinsson, L., & Goadsby, P. J. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.127 · Cited by 523
Self-citationBlumenfeld, A. M., Bloudek, L. M., Becker, W. J., Buse, D. C., Varon, S. F., Maglinte, G. A., Wilcox, T. K., Kawata, A. K., & Lipton, R. B. (2013) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12055 · Cited by 380
Dodick, D. W., Goadsby, P. J., Silberstein, S. D., Lipton, R. B., Olesen, J., Ashina, M., Wilks, K., Kudrow, D., Kroll, R., Kohrman, B., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70209-1 · Cited by 372
Self-citationDodick, D. W., Goadsby, P. J., Spierings, E. L. H., Scherer, J. C., Sweeney, S. P., & Grayzel, D. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70128-0 · Cited by 368
Self-citationSun, H., Dodick, D. W., Silberstein, S., Goadsby, P. J., Reuter, U., Ashina, M., Saper, J., Cady, R., Chon, Y., Dietrich, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00019-3 · Cited by 358
Self-citationLipton, R. B., Stewart, W. F., Sawyer, J., & Edmeads, J. G. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2001.01156.x · Cited by 338
Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention
Lipton, R. B., & Silberstein, S. D. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12505_2 · Cited by 322
Self-citationBigal, M. E., Dodick, D. W., Rapoport, A. M., Silberstein, S. D., Ma, Y., Yang, R., Loupe, P. S., Burstein, R., Newman, L. C., & Lipton, R. B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00249-5 · Cited by 287
Self-citationBigal, M. E., Edvinsson, L., Rapoport, A. M., Lipton, R. B., Spierings, E. L. H., Diener, H.-C., Burstein, R., Loupe, P. S., Ma, Y., Yang, R., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00245-8 · Cited by 261
Self-citationClinical course in migraine: Conceptualizing migraine transformation
Bigal, M. E., & Lipton, R. B. (2008) · Neurology · doi:10.1212/01.wnl.0000325565.63526.d2 · Cited by 210
Self-citationBuse, D. C., Scher, A. I., Dodick, D. W., Reed, M. L., Fanning, K. M., Manack Adams, A., & Lipton, R. B. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.02.013 · Cited by 197
Self-citationPreventive treatment in migraine and the new US guidelines
Estemalik, E., & Tepper (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s33769 · Cited by 123
Lipton, R. B., Stewart, W. F., Sawyer, J. P. C., & Edmeads, J. G. (2001) · Headache The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.01156.x · Cited by 102
Migraine diagnosis: Screening items, instruments, and scales
Peng, K.-P., & Wang, S.-J. (2012) · Acta Anaesthesiologica Taiwanica · doi:10.1016/j.aat.2012.05.002 · Cited by 59
Cited by
Ashina, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1915327 · Cited by 816
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
Kaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Ferrari, M. D., Diener, H. C., Ning, X., Galic, M., Cohen, J. M., Yang, R., Mueller, M., Ahn, A. H., Schwartz, Y. C., Grozinski-Wolff, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31946-4 · Cited by 417
Self-citationSacco, S., Amin, F. M., Ashina, M., Bendtsen, L., Deligianni, C. I., Gil-Gouveia, R., Katsarava, Z., MaassenVanDenBrink, A., Martelletti, P., Mitsikostas, D.-D., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01431-x · Cited by 410
Metadata
- Authors
- Dodick, D. W., Silberstein, S. D., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2018-05-15
- Volume
- 319
- Issue
- 19
- Pages
- 1999
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2803715733
- Cited by
- 562
- References
- 25
- FWCI
- 43.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.